The European Medicines Agency has granted conditional marketing authorization for Durveqtix, a gene therapy for severe and moderately severe hemophilia B, and Adzynma, an enzyme replacement therapy for congenital thrombotic thrombocytopenic purpura, addressing unmet medical needs in these rare conditions.
Chicken fibroblasts can be efficiently transdifferentiated into muscle cells and simultaneously induced to deposit fat, enabling the production of cultured meat with customizable intramuscular fat content.
AbDiffuser introduces a novel approach to generating antibodies by leveraging domain knowledge and physics-based constraints, resulting in high-quality structures and sequences.